126 related articles for article (PubMed ID: 31748013)
1. Hypocrellin B Encapsulated in Triphenyl Phosphonium-Modified Cationic Liposomes for Photodynamic Treatment of Exudative Age-Related Macular Degeneration.
Chen H; Deng H; Zou X; Zhao J
J Biomed Nanotechnol; 2019 Dec; 15(12):2305-2320. PubMed ID: 31748013
[TBL] [Abstract][Full Text] [Related]
2. Liposomal hypocrellin B as a potential photosensitizer for age-related macular degeneration: pharmacokinetics, photodynamic efficacy, and skin phototoxicity in vivo.
Li T; Hou X; Deng H; Zhao J; Huang N; Zeng J; Chen H; Gu Y
Photochem Photobiol Sci; 2015 May; 14(5):972-81. PubMed ID: 25793654
[TBL] [Abstract][Full Text] [Related]
3. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration.
Becerra EM; Morescalchi F; Gandolfo F; Danzi P; Nascimbeni G; Arcidiacono B; Semeraro F
Curr Drug Targets; 2011 Feb; 12(2):149-72. PubMed ID: 20887246
[TBL] [Abstract][Full Text] [Related]
4. Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.
Zuluaga MF; Mailhos C; Robinson G; Shima DT; Gurny R; Lange N
Invest Ophthalmol Vis Sci; 2007 Apr; 48(4):1767-72. PubMed ID: 17389510
[TBL] [Abstract][Full Text] [Related]
5. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2.
Renno RZ; Terada Y; Haddadin MJ; Michaud NA; Gragoudas ES; Miller JW
Arch Ophthalmol; 2004 Jul; 122(7):1002-11. PubMed ID: 15249365
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic therapy for polypoidal choroidal vasculopathy.
Nowak-Sliwinska P; van den Bergh H; Sickenberg M; Koh AH
Prog Retin Eye Res; 2013 Nov; 37():182-99. PubMed ID: 24140257
[TBL] [Abstract][Full Text] [Related]
7. [Novel approach for management of age-related macular degeneration--antiangiogenic therapy and retinal regenerative therapy].
Tamaki Y
Nippon Ganka Gakkai Zasshi; 2007 Mar; 111(3):232-68; discussion 269. PubMed ID: 17402564
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo antitumor activity of a novel hypocrellin B derivative for photodynamic therapy.
Zhao H; Yin R; Chen D; Ren J; Wang Y; Zhanga J; Deng H; Wang Y; Qiu H; Huang N; Zou Q; Zhao J; Gu Y
Photodiagnosis Photodyn Ther; 2014 Jun; 11(2):204-12. PubMed ID: 24534694
[TBL] [Abstract][Full Text] [Related]
9. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration.
Ahn JK; Moon HJ
Am J Ophthalmol; 2009 Nov; 148(5):718-724.e1. PubMed ID: 19674731
[TBL] [Abstract][Full Text] [Related]
10. Release of regulators of angiogenesis following Hypocrellin-A and -B photodynamic therapy of human brain tumor cells.
Deininger MH; Weinschenk T; Morgalla MH; Meyermann R; Schluesener HJ
Biochem Biophys Res Commun; 2002 Nov; 298(4):520-30. PubMed ID: 12408983
[TBL] [Abstract][Full Text] [Related]
11. Photodynamic therapy for age-related macular degeneration treatment: epidemiological and clinical analysis of a long-term study.
Mataix J; Desco MC; Palacios E; Garcia-Pous M; Navea A
Ophthalmic Surg Lasers Imaging; 2009; 40(3):277-84. PubMed ID: 19485292
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
13. Time course and morphology of vascular effects associated with photodynamic therapy.
Schmidt-Erfurth U; Niemeyer M; Geitzenauer W; Michels S
Ophthalmology; 2005 Dec; 112(12):2061-9. PubMed ID: 16325705
[TBL] [Abstract][Full Text] [Related]
14. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of retreatments in a phase 1 and 2 study.
Schmidt-Erfurth U; Miller JW; Sickenberg M; Laqua H; Barbazetto I; Gragoudas ES; Zografos L; Piguet B; Pournaras CJ; Donati G; Lane AM; Birngruber R; van den Berg H; Strong HA; Manjuris U; Gray T; Fsadni M; Bressler NM
Arch Ophthalmol; 1999 Sep; 117(9):1177-87. PubMed ID: 10496389
[TBL] [Abstract][Full Text] [Related]
16. Combined treatment modalities for age related macular degeneration.
Das RA; Romano A; Chiosi F; Menzione M; Rinaldi M
Curr Drug Targets; 2011 Feb; 12(2):182-9. PubMed ID: 20887244
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, tissue distribution and photodynamic therapy efficacy of liposomal-delivered hypocrellin A, a potential photosensitizer for tumor therapy.
Wang ZJ; He YY; Huang CG; Huang JS; Huang YC; An JY; Gu Y; Jiang LJ
Photochem Photobiol; 1999 Nov; 70(5):773-80. PubMed ID: 10568169
[TBL] [Abstract][Full Text] [Related]
18. Polypoidal choroidal vasculopathy and retinochoroidal anastomosis in Japanese patients eligible for photodynamic therapy for exudative age-related macular degeneration.
Obata R; Yanagi Y; Kami J; Takahashi H; Inoue Y; Tamaki Y
Jpn J Ophthalmol; 2006; 50(4):354-360. PubMed ID: 16897221
[TBL] [Abstract][Full Text] [Related]
19. Angiographic features after photodynamic therapy for choroidal neovascularisation in age related macular degeneration and pathological myopia.
Parodi MB; Da Pozzo S; Ravalico G
Br J Ophthalmol; 2003 Feb; 87(2):177-83. PubMed ID: 12543747
[TBL] [Abstract][Full Text] [Related]
20. Photosensitization by anticancer agents 21: new perylene- and aminonaphthoquinones.
Diwu ZJ; Haugland RP; Liu J; Lown JW; Miller GG; Moore RB; Brown K; Tulip J; McPhee MS
Free Radic Biol Med; 1996; 20(4):589-93. PubMed ID: 8904300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
